Projects
A technically viable project is not necessarily a commercially viable project.
Most stalled molecular-energy projects are not stalled on engineering. They are stalled because one commercial component is missing — a buyer, a capital partner, an infrastructure commitment, a technology supplier at the right price. MolecularX identifies which component is missing and helps assemble it.
internal Delivered by MolecularX.
The problem
Project development is where the industry's attrition happens. A project can hold a good study, a willing developer and a real site, and still never reach FID because nobody assembled the counterparties around it. Engineering support does not fix that, and neither does more analysis.
What you end up with
A project with its commercial gaps identified, counterparties in motion against them, and a defensible route to FID.
What this includes
- A clear diagnosis of which commercial components are missing
- Identification of candidate counterparties for each gap — buyers, suppliers, partners, capital
- Commercial structure options and the sequence to pursue them
- Ongoing support through introductions, qualification and negotiation preparation
How we approach it
Map the project against what FID requires
Offtake, technology, EPC, capital, infrastructure, permits. The gaps become the workplan.
Attack the binding constraint
Usually offtake or capital. Working the easy gaps while the binding one stays open is how years disappear.
Bring specific counterparties
This is the difference from advisory work — the output includes named organisations and introductions, not a category description.
Keep the commercial case live
Every component that lands changes the economics. The case is maintained, not filed.
Questions
Do you guarantee that a project reaches FID?
No, and nobody honestly can. Projects fail for reasons outside any adviser's control — policy shifts, capital markets, a buyer's own strategy change. What MolecularX commits to is identifying what is missing and working actively to assemble it.
Is this a success-fee arrangement?
Engagement structures vary by scope and are agreed case by case. Where a commercial outcome is part of the mandate, an incentive component is a normal conversation.
Do you take equity in projects?
That is not the standard model. MolecularX is a facilitator; the default arrangement is an advisory and commercial mandate.
Related
Feasibility
The study that establishes whether the project is technically and commercially buildable.
Read more →Project Origination
Finding projects and opportunities early — before they become a competitive tender.
Read more →Offtake & Buyer Discovery
Finding and qualifying the buyers a production project needs to be financeable.
Read more →Where are you starting from?
Tell us what you provide, what you need and where you operate. The first conversation is about whether we can actually help, which is a faster question than it sounds.